Prevalence of hepatitis B and C markers among the apparently healthy population of the Kaliningrad Region


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The investigation included people of 9 age groups: less than 1 year, 1-9, 10-14, 15-19, 20-29, 30-39, 40-49, 50-59, and more than 60years old. Serological markers for HBV and HCV were identified using ELISA. HCV RNA and virus genotype were determined in the anti-HCV positive samples. Results. The detection rate of HBsAg averaged 0.4% (95% CI: 0.11-1.01%) and that of anti-HBs was 17.1% (95% CI: 14.97-19.53%). No HBV and HCV co-infection cases were identified. The detection rate of anti-HCV averaged 2.9% (95% CI: 2.07-4.17%), the prevalence of current HCV infection confirmed by viral RNA detection was 1.8% (95% CI: 1.14-2.82%). The proportion of individuals with current infection among those positive for anti-HCV was 61.3%. The prevalence of current HCV infection in the adult population (aged 20 to 50 years) of the Kaliningrad Region was 3.1% (95% CI: 1.9-5.0%), which was significantly higher than that in the children and adolescents aged less than 19 years (p < 0.05). The most common HCV genotypes were 1a (21%), 1b (37%), and 3a (32%). Conclusion. The Kaliningrad Region is characterized by a high prevalence of HCV infection in the general population with relatively rare cases of HBV infection. The individuals over 19 years of age are at increased risk for HCV infection and should be included in screening programs. The region shows a high HCV genotypic diversity; genotypes 1a, 1b, and 3a are most common. This distinguishes to a large extent the Kaliningrad Region from all other Russian regions, where genotype 1a is rare.

Full Text

Restricted Access

About the authors

Karen K. Kyuregyan

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: karen-kyuregyan@yandex.ru
BD, Head, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine; Leading Researcher, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

Olga V. Isaeva

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: isaeva.06@mail.ru
Cand. Biol. Sci., Leading Researcher, Department of Viral Hepatitis; Leading Researcher, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

Vera S. Kichatova

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: vera_kichatova@mail.ru
Researcher, Department of Viral Hepatitis; Leading Researcher, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

Anastasia A. Karlsen

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: karlsen12@gmail.com
Researcher, Department of Viral Hepatitis; Researcher, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

Maria A. Lopatukhina

I.I. Mechnikov Research Institute for Vaccines and Sera

Email: m.lopatukhina@gmail.com
Researcher, Laboratory of Viral Hepatitis Moscow, Russia

Ilya A. Potemkin

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: axi0ma@mail.ru
Researcher, Laboratory of Viral Hepatitis; Researcher, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine Moscow, Russia; Moscow, Russia

Fedor A. Asadi Mobarhan

I.I. Mechnikov Research Institute for Vaccines and Sera

Email: 1amfa@bk.ru
Researcher, Laboratory of Viral Hepatitis Moscow, Russia

Elena Yu. Malinnikova

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: malinacgb@mail.ru
MD, Head, Department of Virology; Leading Researcher, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

Olga G. Krasnova

Infectious Diseases Hospital of the Kaliningrad Region

Email: inf-bol@infomed39.ru
Head Physician Kaliningrad, Russia

Igor B. Ivanov

Infectious Diseases Hospital of the Kaliningrad Region

Email: inf-bol@infomed39.ru
Deputy Head Physician. Infectious Diseases Hospital of the Kaliningrad Region Kaliningrad, Russia

Elena V. Rukosueva

Infectious Diseases Hospital of the Kaliningrad Region

Email: rukosueva75@list.ru
Head, Hepatology Room, AIDS Center Kaliningrad, Russia

Olga O. Znoyko

A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of Russia

Email: olgaznoyko@yandex.ru
MD, Associate Professor, Department of Infectious Diseases and Epidemiology Moscow, Russia

Nikolay D. Yushchuk

A.I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Health of Russia

Email: prof.uyshuk@gmail.com
Prof.; Academician of the Russian Academy of Sciences, Head, Department of Infectious Diseases and Epidemiology; President Moscow, Russia

Mikhail I. Mikhailov

Russian Medical Academy of Continuing Professional Education Ministry of Health of Russia; I.I. Mechnikov Research Institute for Vaccines and Sera

Email: michmich2@yandex.ru
Prof.; Corresponding Member of the Russian Academy, MD, Research Adviser; Head, Laboratory of Viral Hepatitis Moscow, Russia; Moscow, Russia

References

  1. Klushkina V.V., Kyuregyan K.K., Kozhanova T.V., Popova O.E., Dubrovina P.G., Isaeva O. V. Impact of universal hepatitis B vaccination on prevalence, infection-associated morbidity and mortality, and circulation of immune escape variants in Russia. PLoS One 2016; 11(6), e0157161. doi: 10.1371/journal.pone.0157161
  2. Global health sector strategy on viral hepatitis 2016-021. Geneva: WHO, 2016. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng. pdf?ua=1
  3. Численность населения Российской Федерации по муниципальным образованиям на 1 января 2019 года. http://www.gks.ru/free_doc/doc_2019/bul_dr/mun_obr2019.rar
  4. WHO guidelines on hepatitis B and C testing. Geneva: WHO, 2017. Licence: CC BY-NC-SA 3.0 IGO
  5. Bian J., Schreiner A.D. Population-based screening of hepatitis C virus in the United States. Current Opinion in Gastroenterology 2019; 35(3): 177-82. doi: 10.1097/MOG.0000000000000520
  6. Кюрегян К.К., Соболева Н.В., Карлсен А.А., Кичатова В.С., Потемкин И.А., Исаева О.В. и др. Динамические изменения распространенности вируса гепатита С среди населения Республики Саха (Якутия) за последние 10 лет. Инфекционные болезни: новости, мнения, обучение 2019; 8(2): 16-26. doi: 10.24411/2305-3496-2019-12002
  7. Kyuregyan K.K., Malinnikova E.Y., Soboleva N.V., Isaeva O.V., Karlsen А.А. et al. Community screening for hepatitis C virus infection in a low-prevalence population. BMC Public Health 2019; 19(1): 1038. doi: 10.1186/s12889-019-7388-7
  8. Kartashev V., Döring M., Nieto L., Coletta E., Kaiser R., et al. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J. Clin. Virol. 2016; 81, 82-9. doi: 10.1016/j.jcv.2016.05.010
  9. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49(S5): S45-S55. https://doi. org/10.1002/hep.22898
  10. Ganem D., Prince A.M. Hepatitis B virus infection - natural history and clinical consequences. New Engl. J. Med. 2004; 350(11): 1118-29. doi: 10.1056/NEJMra031087
  11. Семенов А.В., Останкова Ю.В. Распространенность оккультного вирусного гепатита В среди доноров крови. Вестник гематологии 2018; 14(4): 45-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies